Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher F Nicodemus

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancerJonathan Berek, Peyton Taylor, William McGuire, et al.
The American Journal of Pathology|February 4, 2014
Discordant biological and toxicological species responses to TLR3 activationWilliam M Mitchell, Christopher F Nicodemus, William A Carter, et al.
American Journal of Obstetrics and Gynecology|July 16, 2003
Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancerVolker J Möbus, Richard P Baum, Marcus Bolle, et al.
Gynecologic Oncology|August 7, 2004
CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patientsAlan N Gordon, Birgit C Schultes, Holly Gallion, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 25, 2009
The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancerPatricia Braly, Christopher F Nicodemus, Christina Chu, et al.
Cancer Immunology, Immunotherapy : CII|December 1, 2011
Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cellsTracy R Daniels, Richard K Leuchter, Rafaela Quintero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2004
Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancerJonathan S Berek, Peyton T Taylor, Alan Gordon, et al.
BMC Cancer|April 19, 2013
A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapyTracy R Daniels-Wells, Gustavo Helguera, Richard K Leuchter, et al.
American Journal of Clinical Oncology|September 13, 2019
Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic AdenocarcinomaChi Lin, Vivek Verma, Audrey Lazenby, et al.
Cancer Immunology, Immunotherapy : CII|December 6, 2017
Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumorsKamiya Mehla, Jarrod Tremayne, James A Grunkemeyer, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancerJonathan Berek, Peyton Taylor, William McGuire, et al.
The American Journal of Pathology|February 4, 2014
Discordant biological and toxicological species responses to TLR3 activationWilliam M Mitchell, Christopher F Nicodemus, William A Carter, et al.
American Journal of Obstetrics and Gynecology|July 16, 2003
Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancerVolker J Möbus, Richard P Baum, Marcus Bolle, et al.
Gynecologic Oncology|August 7, 2004
CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patientsAlan N Gordon, Birgit C Schultes, Holly Gallion, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 25, 2009
The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancerPatricia Braly, Christopher F Nicodemus, Christina Chu, et al.
Cancer Immunology, Immunotherapy : CII|December 1, 2011
Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cellsTracy R Daniels, Richard K Leuchter, Rafaela Quintero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2004
Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancerJonathan S Berek, Peyton T Taylor, Alan Gordon, et al.
BMC Cancer|April 19, 2013
A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapyTracy R Daniels-Wells, Gustavo Helguera, Richard K Leuchter, et al.
American Journal of Clinical Oncology|September 13, 2019
Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic AdenocarcinomaChi Lin, Vivek Verma, Audrey Lazenby, et al.
Cancer Immunology, Immunotherapy : CII|December 6, 2017
Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumorsKamiya Mehla, Jarrod Tremayne, James A Grunkemeyer, et al.
Pageof 3